2289585-58-4

2289585-58-4 structure

Name: anti-TNBC agent-1
Chemical Name: anti-TNBC agent-1
CAS Number: 2289585-58-4
Molecular Formula: C₂₆H₃₀O₇
Molecular Weight: 454.51
Catalog: Signaling Pathways Apoptosis Apoptosis
Create Date: 2022-03-01 18:43:02
Modify Date: 2024-01-03 16:50:24
anti-TNBC agent-1 is a potent anti-triple-negative breast cancer (TNBC) agent. anti-TNBC agent-1 exhibits potent activity against different breast cancer cells with IC50 values ranging from 0.20 μM to 0.27 μM. anti-TNBC agent-1 induces apoptosis of SUM-159 cells through mitochondria pathway and causes G1 phase arrest of SUM-159 cells[1].

Name	anti-TNBC agent-1

Description	anti-TNBC agent-1 is a potent anti-triple-negative breast cancer (TNBC) agent. anti-TNBC agent-1 exhibits potent activity against different breast cancer cells with IC50 values ranging from 0.20 μM to 0.27 μM. anti-TNBC agent-1 induces apoptosis of SUM-159 cells through mitochondria pathway and causes G1 phase arrest of SUM-159 cells[1].
Related Catalog	Signaling Pathways >> Apoptosis >> Apoptosis Research Areas >> Cancer
In Vitro	anti-TNBC agent-1 (compound 7) exhibits potent activity against MDA-MB231, SUM-159, MCF-7, Bcap-37, 4T1 cells with IC50 values ranging from 0.20 μM to 0.27 μM. anti-TNBC agent-1 shows 11.6- to 18.6-fold improvement comparing to that of the parent compound parthenolide with IC50 values of 2.68-4.63 μM. anti-TNBC agent-1 is more active than the positive control drug Adriamycin (ADR)[1]. anti-TNBC agent-1 (2 μM and 5 μM; 48 hours; SUM-159 cells) exhibits significant stronger effect on induction of cell apoptosis compared with that of Parthenolide[1]. anti-TNBC agent-1 has selective cytotoxicity against breast cancer cells (IC50=0.22 μM) being compared with 3T3 cells (IC50=8.13 μM)[1].
References	[1]. Ge W, et al. Synthesis and structure-activity relationship studies of parthenolide derivatives as potential anti-triple negative breast cancer agents. Eur J Med Chem. 2019;166:445-469.

Molecular Formula	C₂₆H₃₀O₇
Molecular Weight	454.51